Evotec's Share Price Keeps Digging While Its Deal Machine Keeps Whirring

Evotec stock slides to €3.19, near 52-week low, despite multiple partnerships. Revenue down 20% in H1 2026, guidance cut, takeover speculation swirls.

The gap between what Evotec's partnership announcements promise and what its share price delivers has rarely been wider. The Hamburg-based biotech closed Tuesday at €3.19, down 1.0 percent on the day and barely 1.6 percent above the 52-week low of €3.14 struck just days earlier. A slide beneath the psychologically significant €3 threshold is now a live risk, according to chart watchers.

That fragility stands in sharp relief against the company's steady drumbeat of scientific collaborations. A research pact with Plectonic Biotech unveiled just over a week ago — focused on T-cell engager strategies against solid tumors — failed to arrest the decline, with the stock shedding another 3.0 percent since the announcement. The pattern is becoming familiar: roughly a month ago, a similar AI-focused tie-up with Odyssey Therapeutics was followed by a 7.5 percent drop.

The erosion is cumulative. Evotec shares have lost 41 percent since the start of the year and trade 59 percent below their 52-week high of €7.75. The market capitalization has shrunk to roughly €570.75 million, a valuation that makes the company a more digestible acquisition target than it was twelve months ago — a point not lost on investors nursing takeover speculation.

The fundamental picture does little to reassure. The first-half report for 2026 revealed revenue down nearly a fifth to €300.1 million, a deterioration that the company's confirmation of its lowered full-year guidance roughly two weeks ago only reinforced. Since that guidance cut, the stock has fallen another 5.1 percent. Add a supervisory board resignation about a month ago and a string of analyst downgrades, and the headwinds look formidable.

A formal voting-rights notification filed through the EQS disclosure system last Tuesday added a layer of intrigue without offering clarity. The filing confirms a change in shareholding thresholds but provides no public detail on the size of the move or the investor behind it. Such notifications are legally required when ownership crosses specified thresholds, yet they reveal nothing about strategic intent. The market's response was tellingly muted.

Broker consensus currently lands at "Hold," though that aggregation includes no fresh individual actions from the past two weeks and serves more as a rough compass than a current sentiment gauge.

What emerges is a company whose scientific engine continues to produce partnership after partnership, yet whose stock remains trapped near its floor. The collaborations demonstrate operational momentum; the share price demonstrates that investor trust has not yet returned. Whether takeover speculation crystallizes into something concrete or operational progress finally shifts sentiment will determine whether Evotec can defend the €3 line — or whether that level becomes just another waypoint on a longer descent.